N/A
N=215
BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium
Stage IV Non-small Cell Lung Cancer
Bottom Line
View on ClinicalTrials.gov: NCT03959137 ↗Enrolled (actual)
215
Serious AEs
6.1%
Results posted
Sep 2021
Primary outcome: Primary: The Study Outcome is Defined as the Systemic Treatment Choice. — 26; 68; 0; 99 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- None - Common practice (Other)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- MSD Belgium BVBA
- Primary completion
- Oct 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Study Outcome is Defined as the Systemic Treatment Choice. |
26; 68; 0; 99; 0; 16 | — |
Summary
The treatment landscape of metastatic non small cell lung cancer (NSCLC) is rapidly evolving. There are new diagnostic and treatment options available in the coming months and years.
New combination treatments will give different solutions to pneumo-oncologists who might be guided by certain patient and tumor characteristics.
The link between patient and tumor characteristics in untreated stage IV non small cell lung cancer (NSCLC) patients and systemic treatment needs further investigation, allowing the identification of possible treatment issues, data gaps and/or areas of improvement.
Eligibility Criteria
Inclusion Criteria
- Have voluntarily agreed to participate by giving written informed consent/assent for the trial.
- Have a histologically or cytologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) on first-line (1L) systemic treatment.
- Have received at least their first dose of the selected systemic treatment and a maximum of 1 cycle of the same treatment. Patients that were selected to receive best supportive care will not have to comply to this inclusion criterion.
- Be ≥ 18 years of age on day of signing informed consent.
Exclusion Criteria
- Has received prior systemic treatment for their metastatic non-small cell lung cancer (NSCLC) before the first dose of trial treatment. However, subjects who received adjuvant or neoadjuvant therapy during an earlier stage of their disease, but evolved to stage IV, are eligible.
- Tyrosine kinase inhibitor (TKI) selected as first-line systemic treatment.
- Is participating in an interventional trial or medical need program.
Data sourced from ClinicalTrials.gov (NCT03959137). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.